Cutaneous melanoma remains a significant contributor to mortality in Canada, with an incidence rate of 20.75 cases per 100,000 individuals diagnosed each year.4,5 Recently, a group of Canadian physicians from melanoma-related fields have advocated for the adoption of reflex BRAF testing, extending its scope to clinical stage IIB and IIC of melanoma cases.6 Their rationale emphasizes the urgency of molecular profiling in these stages to initiate therapeutic interventions promptly, acknowledging the heightened risk for disease progression. This evidence concerns the gene BRAF and melanoma.